Capecitabine: Fixed daily dose and continuous (noncyclic) dosing schedule

Cancer Investigation

Volumn 22, Issue 5, 2004, Pages 713-717

  Lokich, Jacob ^a  

^a Cancer Center of Boston   (United States)

Author keywords

Capecitabine; Dosing; Schedule

Indexed keywords

CAPECITABINE; CISPLATIN; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; PACLITAXEL; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG TOLERABILITY; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; IDIOPATHIC DISEASE; INCIDENCE; KIDNEY CARCINOMA; LOW DRUG DOSE; MALE; MAXIMUM PERMISSIBLE DOSE; PANCREAS CANCER; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 11244271494     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-200032976     Document Type: Article

References (11)

1. Budman, D.R.; Meropol, N.J.; Reigner, B.; Creaven, P.; Lichtman, S.M.; Berghora, E.; et al. Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine. J. Clin. Oncol. 1998, 16, 1795-1802.
2. Mackean, M.; Planting, A.; Twelves, C.; Schellens, J.; Allman, D.; Osterwalder, B.; et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol. 1998, 16, 2977-2985.
3. Van Cutsem, E.; Findlay, M.; Osterwalder, B.; Kocha, W.; Dalley, D.; Pazdur, R.; et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J. Clin. Oncol. 2000, 18, 1337-1345.
4. Hoff, P.M.; Ansari, R.; Batist, G.; Cox, J.; Kocha, W.; Kuperminc, M.; et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J. Clin. Oncol. 2001, 19, 2282-2292.
5. Van Cutsem, E.; Twelves, C.; Cassidy, J.; Allman, D.; Bajetta, E.; Boyer, M.; et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J. Clin. Oncol. 2001, 19, 4097-4106.
6. Sobero, A.F.; Aschele, C.; Bertino, J.R. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J. Clin. Oncol. 1997, 15, 368-381.
7. Miller, A.A.; Rosner, G.L.; Egorin, M.J.; et al. Prospective evaluation of body surface area (BSA) as a determinant of paclitaxel pharmacokinetics/ pharmacodynamics in women with solid tumors. Proc. ASCO 2003, 22, 125 (Abstr. 500).
8. Lokich, J.J.; Ahlgren, J.; Gullo, J.; et al. A prospective randomized comparison of continuous infusiona 5-fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. JCO 1989, 7, 425-432.
9. Cassidy, J.; Twelves, C.; Van Cutsem, E.; Hoff, F.; Bajetta, E.; Boyer, M.; et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol. 2002, 13, 566-575.
10. Dunst, J.; Reese, T.; Sutter, T.; Zuhlke, H.; Hinke, A.; Kolling-Schlebusch, J.; Frings, S. Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. J. Clin. Oncol. 2002, 20, 3983-3991.
11. Tebbutt, N.; Norman, A.; Cunningham, D.; et al. Randomized, multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced esophagogastric ancer, interim analysis. Proc. ASCO 2002, 21, Abstract 523.